We conducted an expansive FTO review of the bi-specific antibody space for a small client seeking to be acquired by a high-profile organization in the same space. We screened thousands of results to help determine the client’s freedom to operate. Based on our analysis of the FTO study we confirmed the client’s ability to operate freely in this space, thereby making acquisition more appealing to a third party and the client’s asking price significantly higher.
Bi-Specific Antibody Study
- Post author:Michael McGurk
- Post published:June 2, 2020
- Post category:Intellectual Property Client Projects
Tags: Life Science
Please Share This Share this content
Mike McGurk has more than 30 years of experience in virtually all aspects of patent law. Working with clients ranging from small start-ups to large Fortune 100 companies, he provides counsel in due diligence matters, global portfolio development and adversarial proceedings, including litigation, post-grant reviews, interferences and re-examinations. Mike works primarily with pharmaceutical, chemical, medical device and mechanical technology businesses. For at least the last fifteen (15) years, approximately 50-70% of Mike’s work has been focused in life sciences, including ANDA litigation support and pre-filing due diligence. Mike’s practice is informed by his background as a patent examiner in the chemical arts for the United States Patent and Trademark Office (USPTO), as a litigator for ten years, and as an expert in due diligence matters. He regularly provides strategic litigation counseling support to clients across the nation, and has handled numerous patent matters before the Patent Trial and Appeal Board of the USPTO. His extensive due diligence experience includes pre-litigation, acquisition, in-license, freedom-to-operate product and/or process clearance, design around, validity and patentability matters. Mike works with teams having the appropriate technical and legal abilities.